首页> 外文期刊>BMC Pulmonary Medicine >Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension
【24h】

Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension

机译:胆红素作为肺动脉高压患者的预后指标

获取原文
           

摘要

Background Liver dysfunction reflects the status of heart failure, with congestion and low perfusion of the liver serving as causative mechanisms. Previous studies demonstrated relationship between the results of liver function test and the prognosis in patients with heart failure. However, few studies have examined this relationship in patients with pulmonary arterial hypertension (PAH). Methods The subjects were 37 patients with PAH (8 men and 29 women; 18 with idiopathic PAH and 19 with connective tissue disease-associated PAH). A blood test was performed after a 3-month period free from hospitalization and without changes in functional class, treatment, heart sounds, body weight, or heart rate. Results In a mean follow-up period of 635 ± 510 days, 12 patients died due to heart failure, 2 died due to pulmonary hemorrhage, and 23 patients survived. Cox proportional hazard analyses identified functional class (p 1.2 mg/dL; p Conclusion Elevated serum bilirubin is a risk factor for death in patients with PAH.
机译:背景肝功能不全反映了心力衰竭的状态,其中肝的充血和低灌注是其致病机制。先前的研究证明了心功能不全患者肝功能测试结果与预后之间的关系。但是,很少有研究检查过肺动脉高压(PAH)患者的这种关系。方法研究对象为37例PAH患者(男8例,女29例;特发性PAH 18例,结缔组织病相关性PAH 19例)。在没有住院的3个月后进行了血液检查,功能等级,治疗,心音,体重或心率没有变化。结果平均随访期为635±510天,其中12例因心力衰竭死亡,2例因肺出血死亡,23例幸存。 Cox比例风险分析确定了功能类别(p 1.2 mg / dL; p结论血清胆红素升高是PAH患者死亡的危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号